570 related articles for article (PubMed ID: 19357413)
1. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
2. Teaching clinicians about drugs--50 years later, whose job is it?
Avorn J
N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
[No Abstract] [Full Text] [Related]
3. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
Gass A; Wilson J
Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
[No Abstract] [Full Text] [Related]
4. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
5. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
6. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
7. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
Vladeck DC
Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
[No Abstract] [Full Text] [Related]
8. Pharmacometrics at FDA: evolution and impact on decisions.
Powell JR; Gobburu JV
Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
[TBL] [Abstract][Full Text] [Related]
9. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
Purnhagen KP
Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
[No Abstract] [Full Text] [Related]
10. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
11. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
[No Abstract] [Full Text] [Related]
12. The Neurontin legacy--marketing through misinformation and manipulation.
Landefeld CS; Steinman MA
N Engl J Med; 2009 Jan; 360(2):103-6. PubMed ID: 19129523
[No Abstract] [Full Text] [Related]
13. Forbidden and Permitted Statements about Medications--Loosening the Rules.
Avorn J; Sarpatwari A; Kesselheim AS
N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
[No Abstract] [Full Text] [Related]
14. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
15. Pharmaceutical promotion and First Amendment rights.
Troy DE; Gottlieb S
N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
[No Abstract] [Full Text] [Related]
16. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
17. Pharmaceutical promotion to physicians and First Amendment rights.
Kesselheim AS; Avorn J
N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
[No Abstract] [Full Text] [Related]
18. The Vernacular of Risk--Rethinking Direct-to-Consumer Advertising of Pharmaceuticals.
Greene JA; Watkins ES
N Engl J Med; 2015 Sep; 373(12):1087-9. PubMed ID: 26287749
[No Abstract] [Full Text] [Related]
19. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
20. A historical perspective of pharmaceutical promotion and physician education.
Podolsky SH; Greene JA
JAMA; 2008 Aug; 300(7):831-3. PubMed ID: 18714063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
